Table 2 Co-variates of cases of COVID-19.

Case number	1	2	3	4	5
Sex	Female	Male	Female	Male	Female
Age, y	41	47	46	65	89
CML phase at diagnosis	CP	AP	AP	CP	CP
Co-morbidity	Hypertension	None	Diabetes	Hypertension	Coronary heart disease
Interval from diagnosis of CML to diagnosis of COVID-19, mo	0	121	27	23	133
Current TKI^a	Flumatinib	HQP1351	Imatinib	Imatinib	Imatinib
TKI response at diagnosis of COVID-19	No CHR	MMR	No CHR	MMR	CCyR
Contact with suspected or confirmed persons	No	No	No	Yes	No
Symptom of onset
Fever	Yes	Yes	Yes	Yes	No
Cough	Yes	Yes	No	Yes	Yes
Dyspnoea	No	No	No	Yes	Yes
Sore throat	Yes	Yes	No	No	No
Fatigue	Yes	Yes	Yes	Yes	Yes
Diarrhoea	No	No	Yes	No	No
Laboratory co-variates
WBC × 10E+9/L	108.25	4	7.25	2.28	5.13
Neutrophils × 10E+9/L	89.2	2.61	4.92	1.27	4.5
Lymphocytes × 10E+9/L	4.75	0.78	0.94	0.58	0.17
Haemoglobin, g/L	107	96	40	93	72.5
Platelets × 10E+9/L	487	298	97	297	77.4
Typical findings on lung CT scan	Yes	No	Yes	Yes	Yes
Diagnosis of COVID-19	Confirmed	Confirmed	Confirmed	Confirmed	Probable
Severity of COVID-19	Common	Mild	Common	Common	Critical
Duration from COVID-19 onset to discharge or death, days	34	16	15	47	7
Outcome of COVID-19	Cured	Cured	Cured	Cured	Dead
TKI interruption during COVID-19	No	Yes	No^b	No	No

CML chronic myeloid leukaemia, COVID-19 coronavirus disease 2019, CT computed tomography, mo month(s), TKI tyrosine kinase-inhibitor, y years.
^aCase 1 started flumatinib therapy after 14 days of symptom onset of COVID-19.
^bCase 3 switched to dasatinib because of imatinib resistance when her lung CT scan was near normal and the SARS-CoV-2 RT-PCR test was negative.

Quick links

Search